Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Integrating genetic and lung tissue proteomics data to identify susceptibility proteins for lung cancer.

Created on 19 Nov 2026

Authors

Shuai Xu, Jiajun Shi, Xiao-Ou Shu, Ran Tao, Yongchao Dou, Xingyi Guo, Wanqing Wen, Yaohua Yang, Bing Zhang, Jie Wu, Stephen A Deppen, Bingshan Li, Wei Zheng, Jirong Long, Qiuyin Cai

Published in

Journal of the National Cancer Institute. Nov 19, 2026. Epub Nov 19, 2026.

Abstract

Proteins directly impact disease development and act as drug targets. We integrated genetic and lung tissue proteomic data to identify lung cancer susceptibility proteins and evaluated them as candidate drug targets.
We profiled the proteome and genome in 200 non-neoplastic lung tissue samples and constructed genetic models to predict protein abundance. These models were applied to genome-wide association study (GWAS) data of 55,174 lung cancer cases and 1,294,174 controls to evaluate associations between predicted abundance and lung cancer risk overall and by major histological subtypes. Independent lung tissue proteomic data was used for cross-dataset evaluation, followed by colocalization and summary-data-based Mendelian randomization. Prioritized proteins were cross-referenced against drug databases.
We identified 29 lung cancer risk-associated proteins at a false discovery rate < 5%, including 25 for overall lung cancer, two (AQP3 and IL18) specific to adenocarcinoma, and two (HMGN2 and HLA-DMB) specific to squamous cell carcinoma. Genes encoding 15 proteins are located > 2Mb away from known GWAS risk loci. Among the remaining 14 proteins at known risk loci, five (EPHX2, CLDN18, PSMD5, ARHGAP27, and CYP2S1) showed associations independent of proximal lead variant. Of the 29 proteins, eight were predicted and six were significant in independent data. DSP, IL18 and TYMP proteins demonstrated both reproducible and potential causal evidence and are targeted by six drugs that are FDA-approved or in phase III trials.
Our study identified novel lung cancer susceptibility proteins and potential therapeutic targets, offering insights into lung cancer biology and informing future translational research.

PMID:
43055353
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 2
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement